Icon Group’s compounding arm, Slade Health today officially opened a state-of-the-art in-house specialist Drug Stability Testing and Research Laboratory in Sydney; the first-of-its-kind in Australia. Located at Slade’s Mt Kuring-gai facility, the laboratory has been introduced to remove some of the systemic barriers within cancer care infrastructure by improving the ability to deliver the latest, most innovative treatments.
Compounding of cancer treatments must be completed under very controlled sterile conditions to ensure patient safety, and most compounded doses have a very limited shelf-life – often only 24 hours. With a 24-hour window in which a dose must be administered, this treatment model offers little to no flexibility which means cancer patients, especially those in regional areas, must travel sometimes hundreds of kilometers to receive their treatment in metropolitan areas.
